Recent Comments

Comment RSS

Dopamine News and Research RSS Feed - Dopamine News and Research

Dopamine is a hormone and neurotransmitter occurring in a wide variety of animals, including both vertebrates and invertebrates. In the brain, this phenethylamine functions as a neurotransmitter, activating the five types of dopamine receptors — D1, D2, D3, D4 and D5, and their variants. Dopamine is produced in several areas of the brain, including the substantia nigra and the ventral tegmental area. Dopamine is also a neurohormone released by the hypothalamus. Its main function as a hormone is to inhibit the release of prolactin from the anterior lobe of the pituitary. Dopamine has many functions in the brain, including important roles in behavior and cognition, motor activity, motivation and reward, inhibition of prolactin production (involved in lactation), sleep, mood, attention, and learning. Dopaminergic neurons (i.e., neurons whose primary neurotransmitter is dopamine) are present chiefly in the ventral tegmental area (VTA) of the midbrain, substantia nigra pars compacta, and arcuate nucleus of the hypothalamus.

MONITORING FORCE files for Flibanserin orphan drug status designation with the EMEA

19. November 2009 11:24
MONITORING FORCE GmbH announced that they have filed on November 16th, 2009 Flibanserin in the indication treatment-relevant levodopa-induced dyskinesia in Parkinson's disease for orphan drug status designation with the European Medicines Agency (EMEA). Levodopa-induced dyskinesia is a complication of the mainstay treatment in advanced Parkinson's and a serious burden to some of those affected, since it may be disabling for the patients and preventing them from receiving optimal treatment for Parkinson's. [More]

Posted in: Medical Condition News | Pharmaceutical News

Tags: ,

New mathematical model may hasten drug development for Parkinson's Disease

19. November 2009 01:52
Australian scientists have significantly advanced our understanding of dopamine release from nerve cells, findings that should speed the development of more effective drugs for treating Parkinson's Disease. [More]

Patients with recent-onset schizophrenia have raised levels of inflammatory substances

18. November 2009 11:24
Researchers at the Swedish medical university Karolinska Institutet have discovered that patients with recent-onset schizophrenia have higher levels of inflammatory substances in their brains. Their findings offer hope of being able to treat schizophrenia with drugs that affect the immune system. [More]

BioSante Pharmaceuticals applauds Boehringer Ingelheim for developing a therapy to treat HSDD

17. November 2009 03:13
BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company developing products for female sexual health, including LibiGel® for the treatment of hypoactive sexual desire disorder (HSDD), applauds the efforts of Boehringer Ingelheim to develop a therapy to treat this unmet medical need. [More]

Possible cure for Parkinson's disease

4. November 2009 17:57
Researchers at Iowa State University have found an essential key to possibly cure Parkinson's disease and are looking for others. [More]

Posted in: Medical Research News | Medical Condition News

Tags: , , ,

NuPathe and SurModics sign a drug delivery technology license agreement

3. November 2009 01:48
SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, and NuPathe Inc., a neuroscience-focused specialty pharmaceutical company, announced today that the companies have entered into a license agreement for drug delivery technology. [More]

Stress-evoked changes can precipitate low mood and re-ignite drug-seeking behaviors

31. October 2009 02:45
Stress-evoked changes in circuits that regulate serotonin in certain parts of the brain can precipitate a low mood and a relapse in cocaine-seeking, based on mouse studies published online this week in the Proceedings of the National Academy of Sciences. [More]

Researchers show Simvastatin prevents Parkinson's disease from progressing further

30. October 2009 01:29
Simvastatin, a commonly used, cholesterol-lowering drug, may prevent Parkinson's disease from progressing further. Neurological researchers at Rush University Medical Center conducted a study examining the use of the FDA-approved medication in mice with Parkinson's disease and found that the drug successfully reverses the biochemical, cellular and anatomical changes caused by the disease. [More]

Ipsen announces sales highlights for the first nine months of 2009

29. October 2009 06:00
Ipsen reported today its sales for the third quarter and first nine months of 2009. [More]

Brain cell transplants help replace degenerated neurons, finds Swiss research team

29. October 2009 02:13
A Swiss research team has found that using an animal's own brain cells (autologous transplant) to replace degenerated neurons in select brain areas of donor primates with simulated but asymptomatic Parkinson's disease and previously in a motor cortex lesion model, provides a degree of brain protection and may be useful in repairing brain lesions and restoring function. [More]

Changes in dopamine levels linked to infant learning patterns

27. October 2009 01:59
When do you first leave the nest? Early in development infants of many species experience important transitions-such as learning when to leave the protective presence of their mother to start exploring the wider world. Neuroscientists have now pinpointed molecular events occurring in the brain during that turning point. [More]

Posted in: Medical Science News

Tags: , , , , , , , ,

Antidepressants are not effective for many people

24. October 2009 04:11
More than half the people who take antidepressants for depression never get relief. [More]

Adult male monkeys exposed to cocaine while in the womb have poor impulse control

23. October 2009 05:27
Adult male monkeys exposed to cocaine while in the womb have poor impulse control and may be more vulnerable to drug abuse than female monkeys, even a decade or more after the exposure, according to a new study by researchers at Wake Forest University School of Medicine. The findings could lead to a better understanding of human drug abuse. [More]

Rexahn Pharmaceuticals announces positive results from Phase IIa Serdaxin clinical study

20. October 2009 02:19
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in CNS and oncology, today announced top-line results from a Phase IIa clinical study of Serdaxin™, its major depressive disorder (MDD) drug candidate. [More]

Researchers find the genetic mutation that is linked with changes in brain development

19. October 2009 05:49
For decades, scientists have thought the faulty neural wiring that predisposes individuals to behavioral disorders like autism and psychiatric diseases like schizophrenia must occur during development. Even so, no one has ever shown that a risk gene for the disease actually disrupts brain development. [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.